MRI developer Intermagnetics General has sued GE Medical Systems to prevent an employee from joining GE. In the lawsuit filed Oct. 18 in the Supreme State Court of Albany (NY), Intermagnetics is seeking a preliminary and permanent injunction stopping
MRI developer Intermagnetics General has sued GE Medical Systems to prevent an employee from joining GE. In the lawsuit filed Oct. 18 in the Supreme State Court of Albany (NY), Intermagnetics is seeking a preliminary and permanent injunction stopping Jinhua Huang from accepting employment or commencing work with GE or any other employer in a position in which he will be involved in the design, use, or manufacture of MRI magnet systems or components. Huang had announced that he would start work with GE on Oct. 25.
Latham, NY-based Intermagnetics says that Huang will inevitably disclose to his new employer Intermagnetics MRI systems and processes that constitute the firms trade secrets. According to court filings by Intermagnetics, Huang has been extensively involved in the engineering, design, and development of Intermagnetics MRI magnet systems, and has detailed knowledge of them. In addition, the filings say that Huang had access to and developed numerous trade secrets regarding Intermagnetics MRI systems and processes, including superconducting magnet windings, interfaces, clearances, protection systems, shimming design, computer codes, cryostat spacings, coil mechanics, cold mass suspension, and suspension techniques.
To support its request for an injunction, Intermagnetics referred to an employee confidentiality and proprietary information agreement Huang had signed with Intermagnetics in late 1991 upon joining the firm. In the agreement, Huang promised to maintain in confidence all the firms confidential information and trade secrets, according to Intermagnetics. Intermagnetics says that Huangs conduct constitutes a misappropriation of Intermagnetics trade secrets that will irreparably injure Intermagnetics business, and is also seeking an award of money damages. A GE spokesperson was unavailable for comment.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.